Biotechnology - Inflammatory diseases

Filter

Current filters:

Inflammatory diseases

Popular Filters

1 to 25 of 31 results

Merck KGaA's Allergopharma to collaborate with S-TARget on new generation of allergy products

Merck KGaA's Allergopharma to collaborate with S-TARget on new generation of allergy products

02-09-2014

Allergopharma, a division of Germany’s Merck KGaA, and Austrian allergy biotechnology company S-TARget…

AllergopharmaAustriaBiotechnologyGermanyImmunologyInflammatory diseasesMerck KGaAResearch

J&J affiliate Cilag GmbH International acquires Covagen

J&J affiliate Cilag GmbH International acquires Covagen

25-08-2014

Cilag GmbH International, an affiliate of US health care giant Johnson & Johnson’s Janssen companies,…

Anti-Arthritics/RheumaticsBiotechnologyCilag GmbH InternationalCovagenFynomAbInflammatory diseasesJanssenJohnson & JohnsonMergers & Acquisitions

Celltrion files for US FDA approval of Remsima biosimilar

Celltrion files for US FDA approval of Remsima biosimilar

13-08-2014

South Korean biopharmaceutical firm Celltrion says it has completed the filing procedure to obtain US…

BiosimilarsBiotechnologyCellTrionClinical researchInflammatory diseasesinfliximabJanssen BiotechJohnson & JohnsonPatentsRegulationRemicadeRemsimaUSA

Galapagos plunges as GSK gives up rights to developmental drug

09-08-2014

Along with presenting first-half 2014 financial results today, Belgian biotech group Galapagos said its…

BiotechnologyFinancialGalapagosGlaxoSmithKlineGSK2586184Inflammatory diseasesLicensing

NicOx to acquire Aciex Therapeutics

02-07-2014

Ophthalmology-focused French biotech firm NicOx has entered into an agreement to acquire all of the outstanding…

Aciex TherapeuticsBiotechnologyInflammatory diseasesMergers & AcquisitionsNicOxOphthalmics

High level of innovation seen in psoriasis treatment pipeline

High level of innovation seen in psoriasis treatment pipeline

29-05-2014

Despite mostly targeting established molecules, the psoriasis pipeline is showing a high level of innovation…

BiotechnologyBiotest AGDermatologicalsInflammatory diseasesResearchtregalizumab

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study

10-05-2014

Anglo-Swedish drug major AstraZeneca and the USA’s Amgen have announced that the Phase III AMAGINE-1…

AmgenAstraZenecaBiotechnologybrodalumabInflammatory diseasesResearch

Lupin inks strategic biosimilars joint venture agreement with Yoshindo

23-04-2014

Indian drugmaker Lupin has entered into a strategic joint venture agreement with Japanese pharma company,…

BiosimilarsBiotechnologyEnbrelInflammatory diseasesJapanLicensingLupinTakeda PharmaceuticalYoshindo

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Abide Therapeutics in deal with Celgene on immune disorders research

03-03-2014

Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

Vectura and UCB to collaborate on severe inflammatory disease

Vectura and UCB to collaborate on severe inflammatory disease

30-09-2013

Vectura and UCB have entered into a collaboration for the development of an innovative biologic immuno-modulatory…

BiotechnologyEuropeInflammatory diseasesPharmaceuticalResearchRespiratory and PulmonaryUCBVectura

Novartis enters into a collaboration for Il-17 inhibitor

06-08-2013

US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Teijin and Amgen join forces on autoimmune disease research

31-07-2013

Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

Array BioPharma signs up to $387 million deal

30-07-2013

In a second licensing deal this week US biotech major Celgene (Nasdaq: CELG) has entered into a strategic…

Array BioPharmaBiotechnologyCelgeneInflammatory diseasesLicensing

US FDA approves Janssen's Simponi to treat ulcerative colitis

16-05-2013

The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Concert Pharma in $300 million-plus deal with Celgene

07-05-2013

Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Merck Serono spins out sixth company - Calypso Biotech - to focus on gastrointestinal immunological disorders

05-03-2013

German drug major Merck KGaA's (MRK: DE) subsidiary Merck Serono yesterday (March 4) announced the creation…

BiotechnologyCalypso BiotechGastro-intestinalsInflammatory diseasesMerck KGaAMerck SeronoMergers & Acquisitions

FDA approves SOBI's Kineret for the treatment of NOMID

08-01-2013

Biotech firm Swedish Orphan Biovitrum (STO: SOBI) today announced that the US Food and Drug Administration…

AmgenBiotechnologyInflammatory diseasesKineretNorth AmericaRegulationSobiSwedish Orphan Biovitrum

Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen

07-01-2013

Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer…

BiotechnologyDekavilGlycoVaxynInflammatory diseasesJanssenJohnson & JohnsonLicensingPfizerPharmaceuticalPhilogenVaccines

Phenex in up to $135 million research collaboration with Janssen

17-12-2012

Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S

10-10-2012

Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

1 to 25 of 31 results

Back to top